Humanin
← Back to LibraryCompound Profile
Humanin is reviewed here for cellular energy, stamina, and recovery.
Research Summary
Published literature searches and source-listed protocols
Cellular energy, Stamina, Recovery
Target context: Mitochondrial Receptors
Limited or not established.
Treat protocols as educational examples unless stronger sources are listed.
Route(s)
Subcutaneous
Typical dose
2mg - 5mg
Dosing window
Anytime
Receptor / target
Mitochondrial Receptors
Properties
Not listed
Pre-mixed
No
Protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-6 | 2mg - 5mg twice weekly | Under-researched compared to MOTS-c; dose conservatively. |
Protocol example for research-context comparison; verify against the evidence status and listed medical sources.
Protocol logic check
Medical literature and study context
Medical-source summary: This section ties the page to medical literature, drug labels, trial registries, and regulatory sources. It is educational context only and should not be read as medical advice or a use recommendation.
| Evidence position | No approved FDA label was identified for this entry; evidence should be treated as literature context rather than validated dosing guidance. |
|---|---|
| Where studied | Studied in metabolism, mitochondrial function, substrate use, exercise physiology, glucose handling, or endurance models. |
| Source systems checked | FDA regulatory pages; PubMed/PMC literature; ClinicalTrials.gov records |
| Target and route context | Target/receptor: Mitochondrial Receptors. Route(s): Subcutaneous. Dosing window on page: Anytime. |
| Protocol anchor | No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only. |
| Main evidence limit | Key limitation: literature may be preclinical, indirect, old, region-specific, or sparse; absence of a label means no validated dosing standard. |
Source-linked findings
- Energy/endurance compounds are usually studied through substrate metabolism, mitochondrial function, AMPK/PPAR signaling, glucose handling, or exercise endpoints.
- Sleep disruption, stimulant overlap, cardiovascular strain, and overtraining can distort perceived benefit.
- No approved-label regimen was identified for this entry. Dosing examples should be treated as unverified protocol examples.
Protocol and study notes
- No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only.
- On-page protocol examples summarized for comparison: Standard Protocol: Weeks 1-6, 2mg - 5mg twice weekly.
- Key limitation: literature may be preclinical, indirect, old, region-specific, or sparse; absence of a label means no validated dosing standard.
- Monitor metabolic labs, mitochondrial or fatigue endpoints, cancer history, renal/hepatic context, and overstimulation or sleep changes.
Selected medical sources
Independent evidence
Regulatory status: no approved label identified
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Active malignancy: Humanin's potent anti-apoptotic mechanisms (Bcl-2 upregulation, Bax inhibition, cytochrome c suppression) that protect healthy cells from death are mechanistically identical to the pathways cancer cells exploit to become chemotherapy-resistant; exogenous Humanin may protect tumor cells from apoptosis-inducing therapy.
- Concurrent cytotoxic chemotherapy: Humanin's anti-apoptotic activity directly opposes the mechanism of action of most chemotherapy agents, which rely on triggering apoptosis in rapidly dividing cells.
- Known hypersensitivity to Humanin or peptide excipients.
- Pregnancy: mitochondrial-encoded peptide signaling in fetal development is not characterized; safety not established.
- Breastfeeding: no data.
- Pediatric use: no safety data.
- Severe cardiac arrhythmia: IGF-1 receptor and STAT3 pathway activation by Humanin may affect cardiac electrophysiology at high doses; limited human data.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Injection site reactions: redness, soreness, mild swelling at subcutaneous injection site; standard peptide injection response; expected and manageable.
- Under-documented adverse effects: Humanin has the least human safety data of any compound in Category IV; all side effect characterization derives from animal studies and early-stage human observation; unknown adverse effects may exist that have not yet been documented.
- Theoretical protection of cancer cells from apoptosis: the mechanistically most significant theoretical adverse effect; Bcl-2 upregulation and Bax inhibition are the same pathways that confer chemotherapy resistance in cancer; not observed as a clinical adverse event but represents the primary safety concern.
- Mild fatigue: reported anecdotally in early weeks of use; possibly related to mitochondrial membrane signaling adjustments.
- Mild headache: uncommon; not well characterized.
- Potential IGF-1 receptor pathway modulation: Humanin signals through the IGF-1 receptor at certain concentrations; theoretical implications for insulin-sensitive conditions warrant monitoring in diabetic subjects.
- No documented endocrine disruption, receptor desensitization, or hormonal suppression in available preclinical literature.
Compatibility
The relationships below are heuristic compatibility notes and were not independently verified. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.